SPC394
Voxelotor eða ráphverfa eða lyfjafræðilega viðeigandi salt þess
Status:
VeittApplication date:
29.7.2022Application published:
15.8.2022Grant published:
15.2.2025
Max expiry date:
14.2.2037Medicine name:
OxbrytaMedicine for children:
No
Timeline
Today
29.7.2022Application
15.8.2022Publication
15.2.2025Registration
14.2.2037Expires
Marketing license
IS authorization number:
EU/1/21/1622/001Date:
22.2.2022
Foreign authorization number:
EU/1/21/1622Date:
14.2.2022
Owner
Name:
Global Blood Therapeutics, Inc.Address:
181 Oyster Point Blvd., South San Francisco, CA 94080 US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2797416
Deadlines
TypeDeadline until
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 09.01.2025